Alnylam Pharmaceuticals, Inc. (DUL.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:20AM CEST. Market open.
| Previous Close | 136.65 |
| Open | 138.80 |
| Bid | 142.00 x 12100 |
| Ask | 143.00 x 11900 |
| Day's Range | 138.80 - 138.80 |
| 52 Week Range | 132.95 - 195.40 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | 18.058B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.28 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 184.16 |
ZacksCompared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ZacksAlnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass., May 02, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
© 2024 Yahoo. All rights reserved.